1. Home
  2. WNEB vs STTK Comparison

WNEB vs STTK Comparison

Compare WNEB & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western New England Bancorp Inc.

WNEB

Western New England Bancorp Inc.

N/A

Current Price

$13.16

Market Cap

259.2M

Sector

Finance

ML Signal

N/A

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.10

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WNEB
STTK
Founded
1853
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
259.2M
119.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
WNEB
STTK
Price
$13.16
$3.10
Analyst Decision
Buy
Buy
Analyst Count
2
5
Target Price
$11.00
$4.00
AVG Volume (30 Days)
48.8K
328.1K
Earning Date
01-27-2026
11-06-2025
Dividend Yield
2.13%
N/A
EPS Growth
27.15
N/A
EPS
0.66
N/A
Revenue
$79,080,000.00
$1,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$7.48
N/A
P/E Ratio
$20.01
N/A
Revenue Growth
9.08
N/A
52 Week Low
$7.63
$0.69
52 Week High
$13.45
$3.38

Technical Indicators

Market Signals
Indicator
WNEB
STTK
Relative Strength Index (RSI) 75.41 71.00
Support Level $12.62 $1.93
Resistance Level $13.45 $3.30
Average True Range (ATR) 0.35 0.23
MACD 0.08 0.09
Stochastic Oscillator 82.99 80.69

Price Performance

Historical Comparison
WNEB
STTK

About WNEB Western New England Bancorp Inc.

Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: